Lars Wallentin1, Ziad Hijazi2, Ulrika Andersson2, John H Alexander2, Raffaele De Caterina2, Michael Hanna2, John D Horowitz2, Elaine M Hylek2, Renato D Lopes2, Signild Asberg2, Christopher B Granger2, Agneta Siegbahn2. 1. From the Department of Medical Sciences, Cardiology (L.W., Z.H.), Department of Medical Sciences, Cardiovascular Epidemiology (S.A.), and Department of Medical Sciences, Clinical Chemistry (A.S.), and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (L.W., Z.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (U.A.); Duke University, Medical Center, Durham, NC (J.H.A., R.D.L., C.B.G.); Gabriele d'Annunzio University, Chieti, and Gabriele Monasterio Foundation, Pisa, Italy (R.D.C.); Bristol-Myers Squibb, Princeton, NJ (M.H.); University of Adelaide, Adelaide, Australia (J.D.H.); and Boston University Medical Center, Boston, MA (E.M.H.). Lars.Wallentin@ucr.uu.se. 2. From the Department of Medical Sciences, Cardiology (L.W., Z.H.), Department of Medical Sciences, Cardiovascular Epidemiology (S.A.), and Department of Medical Sciences, Clinical Chemistry (A.S.), and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (L.W., Z.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (U.A.); Duke University, Medical Center, Durham, NC (J.H.A., R.D.L., C.B.G.); Gabriele d'Annunzio University, Chieti, and Gabriele Monasterio Foundation, Pisa, Italy (R.D.C.); Bristol-Myers Squibb, Princeton, NJ (M.H.); University of Adelaide, Adelaide, Australia (J.D.H.); and Boston University Medical Center, Boston, MA (E.M.H.).
Abstract
BACKGROUND: Growth differentiation factor 15 (GDF-15), high-sensitivity troponin, and N-terminal pro-brain natriuretic peptide levels are predictive of death and cardiovascular events in healthy elderly subjects, patients with acute coronary syndrome, and patients with heart failure. High-sensitivity troponin I and N-terminal pro-brain natriuretic peptide are also prognostic in patients with atrial fibrillation. We evaluated the prognostic value of GDF-15 alone and in addition to clinical characteristics and other biomarkers in patients with atrial fibrillation. METHODS AND RESULTS: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial randomized 18 201 patients with atrial fibrillation toapixaban or warfarin. Biomarkers were measured at randomization in 14 798 patients. Efficacy and safety outcomes during 1.9 years of follow-up were compared across quartiles of GDF-15 by use of Cox analyses adjusted for clinical characteristics, randomized treatment, and other biomarkers. The GDF-15 level showed a median of 1383 ng/L (interquartile range, 977-2052 ng/L). Annual rates of stroke or systemic embolism ranged from 0.9% to 2.03% (P<0.001); of major bleeding, from 1.22% to 4.53% (P<0.001); and of mortality, from 1.34% to 7.19% (P<0.001) in the lowest compared with the highest GDF-15 quartile. The prognostic information provided by GDF-15 was independent of clinical characteristics and clinical risk scores. Adjustment for the other cardiac biomarkers attenuated the prognostic value for stroke, whereas the prognostic value for mortality and major bleeding remained. Apixaban consistently reduced stroke, mortality, and bleeding, regardless of GDF-15 levels. CONCLUSIONS:GDF-15 is a risk factor for major bleeding, mortality, and stroke in atrial fibrillation. The prognostic value for major bleeding and death remained even in the presence of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin I. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.
RCT Entities:
BACKGROUND:Growth differentiation factor 15 (GDF-15), high-sensitivity troponin, and N-terminal pro-brain natriuretic peptide levels are predictive of death and cardiovascular events in healthy elderly subjects, patients with acute coronary syndrome, and patients with heart failure. High-sensitivity troponin I and N-terminal pro-brain natriuretic peptide are also prognostic in patients with atrial fibrillation. We evaluated the prognostic value of GDF-15 alone and in addition to clinical characteristics and other biomarkers in patients with atrial fibrillation. METHODS AND RESULTS: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial randomized 18 201 patients with atrial fibrillation to apixaban or warfarin. Biomarkers were measured at randomization in 14 798 patients. Efficacy and safety outcomes during 1.9 years of follow-up were compared across quartiles of GDF-15 by use of Cox analyses adjusted for clinical characteristics, randomized treatment, and other biomarkers. The GDF-15 level showed a median of 1383 ng/L (interquartile range, 977-2052 ng/L). Annual rates of stroke or systemic embolism ranged from 0.9% to 2.03% (P<0.001); of major bleeding, from 1.22% to 4.53% (P<0.001); and of mortality, from 1.34% to 7.19% (P<0.001) in the lowest compared with the highest GDF-15 quartile. The prognostic information provided by GDF-15 was independent of clinical characteristics and clinical risk scores. Adjustment for the other cardiac biomarkers attenuated the prognostic value for stroke, whereas the prognostic value for mortality and major bleeding remained. Apixaban consistently reduced stroke, mortality, and bleeding, regardless of GDF-15 levels. CONCLUSIONS:GDF-15 is a risk factor for major bleeding, mortality, and stroke in atrial fibrillation. The prognostic value for major bleeding and death remained even in the presence of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin I. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.
Authors: Abhinav Sharma; Susanna R Stevens; Joseph Lucas; Mona Fiuzat; Kirkwood F Adams; David J Whellan; Mark P Donahue; Dalane W Kitzman; Ileana L Piña; Faiez Zannad; William E Kraus; Christopher M O'Connor; G Michael Felker Journal: JACC Heart Fail Date: 2017-10 Impact factor: 12.035
Authors: Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel Journal: Heart Rhythm Date: 2016-06-10 Impact factor: 6.343
Authors: Weronica E Ek; Åsa K Hedman; Stefan Enroth; Andrew P Morris; Cecilia M Lindgren; Anubha Mahajan; Stefan Gustafsson; Ulf Gyllensten; Lars Lind; Åsa Johansson Journal: Hum Mol Genet Date: 2015-12-17 Impact factor: 6.150